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Abstract 
Background : To compare the effectiveness of 
topical steroid and oral steroid in reducing size of 
polyps and improving patency of nasal air way. 
Methods:  In this randomized controlled trial a 
total of 140 patients were taken with bilateral nasal 
polypi. They were divided in 2 groups. Group A (70 ) 
were given topical steroids and Group B (70) were 
given oral steroids.  Patients aged above 15 years of 
both genders with bilateral nasal polypi of stage 2 
and 3  were included.  Anterior rhinoscopy was done 
with the help of head-light. Patency was noted of 
both nostrils using nasal speculum. Endoscopic 
staging was done at the same time. Size was assessed 
with rigid endoscope as it can diagnose small polyps 
in the middle meatus. Both groups were examined 
again in follow up by anterior rhinoscopy and then 
by endoscope to see the stage of polyps. Chi square 
test were applied for comparison of efficacy. p value 
≤0.05 was considered significant. 
Results: Mean+SD of age (yrs) of patient in Group 
A and Group B were 43.71+10.756 and 42.77+12.238 
respectively. Chi-square test was applied to compare 
the efficacy (right nostril and left nostril) in both the 
groups which was statistically significant (p-value 
0.009 and 0.005) which showed that topical steroid 
was more effective than systemic steroid in treating 
nasal polyps. 
Conclusion: Topical steroid is significantly 
effective than systemic steroid in treating nasal 
polyps. 
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Introduction 
The nasal polyp (NP) presents as grape like 
appearance, having a ‘body’ and a ‘stalk’. The surface 
is smooth and the colour is more yellow than the pink 
mucous membrane.1 NP usually start in the 
osteomeatal region and block the normal sinus 
ventilation causing facial and sinus pain. NP affect 
more men than women and appear in adults aged 
≥30–40 years of age. Endoscopic sinus surgery is 
frequently used when medical therapy is failed.2 The 
estimated  prevalence of this condition is between 1% 
and 4%.3 Chronic rhinosinusitis with NP is a common 
health problem, affecting 2% to 5% of the general 
population.4 European guidelines recommend 
intranasal corticosteroids as first line treatment for 
chronic rhinosinusitis with nasal polyps, oral steroid 
therapy for patients with severe or uncontrolled 
symptoms and endoscopic sinus surgery for patients 
with inadequate improvement despite oral steroid 
therapy.5 Oral steroids 25mg prednisolone are given 
daily for 10-14 days.1 Intranasal steroids will not 
eliminate polyps, as only a small fraction of the spray 
reaches the middle meatus.1. Benitez and colleagues 
used prednisolone, 30 mg/d, tapered over 2 weeks; 
Hissaria and colleagues used prednisolone, 50 mg /d 
for 2 week without tapering.5 Vaidyanathan and 
colleagues reported a randomized, double blind, 
placebo-controlled trial. Sixty patients with nasal 
polyps  received oral prednisolone, 25mg/d for 2 
weeks, or placebo followed by treatment in both 
groups with fluticasone propionate nasal spray(200μg 
twice daily) for 8 weeks and fluticasone propionate 
nasal spray (200μg twice daily) for 18 additional 
weeks.5  Topical corticosteroid administration 
generally causes fewer adverse effects than systemic 
corticosteroid use because the topical corticosteroids  
has limited bioavailability.6 Topical and oral steroids 
are considered  the first line treatment of chronic 
rhinosinusitis with and without NP.7 The rate of 
success of NP  treatment with a topical corticosteroid 
ranges from 60.9 to 80%.8 A retrospective study 
evaluating a short course oral prednisolone followed 
by daily intranasal steroid showed this treatment to be 
effective in 85% of patients with only 15% of patients 
requiring endoscopic sinus surgery.9  
NP are benign lesions arising from the mucosa of the 
nasal sinuses (commonly at the outflow tract of one or 
more of the sinuses) or from the mucosa of the nasal 
cavity. Having an uncertain etiology and a tendency to 
recur, they represent a challenging diagnosis for the 
physician to treat. Management of NP forms a large 
part of the workload for the otolaryngologist, 
especially for those with an interest in rhinology.10 
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Patients and Methods  
This randomized controlled trial  study was conducted 
in ENT department Fauji Foundation Hospital 
Rawalpindi from Jan,2012 to June,2013. A total of 140 
patients were taken with bilateral nasal polypi. They 
were divided in 2 groups. Group A (70 ) were given 
topical steroids and Group B (70) were given oral 
steroids. Sample size was calculated by using WHO 
sample size calculator and level of significance was 
5%. Consecutive non-probability sampling technique 
was used . Patients aged above 15 years of both 
genders with bilateral nasal polypi of stage 2 and 3 
(mentioned  below) were included in the study. 
Patients with unilateral polypi and having 
comorbidities like diabetes and hypertension were 
excluded from the study. An informed consent was 
obtained from all patients prior to using their data in 
research. Anterior rhinoscopy was done with the help 
of head light. Patency was noted of both nostrils using 
nasal speculum. Endoscopic staging was done at the 
same time. Size was assessed with rigid endoscope as 
it can diagnose small polyps in the middle meatus. It is 
not only useful for the diagnosis but also for follow up 
examination and for staging the disease(Table 1).1 
 
Table 1: Nasal polyps- Endoscopic staging 
Endoscopic Findings Stage 
No polyp 0 
Restricted to middle meatus 1 
Below middle turbinate 2 
Massive polyposis 3 
 
 Fluticasone propionate (flixonase) nasal spray two 
puffs per nostril twice daily for four weeks were given 
to group A. 30mg of prednisolone for four weeks 
(three tablets BD) were given to group B. Group A and 
B were followed up after four weeks. Both groups 
were examined again in follow up by anterior 
rhinoscopy and then by endoscope to see the stage of 
polyps.Patients were examined and findings were 
confirmed by senior or/and supervisor. Nasal patency 
was checked by nasal speculum.  Chi square test was 
applied for comparison of efficacy. p value ≤0.05 was 
considered significant.  
 
Results 
Total 140 patients were examined having bilateral 
nasal polypi during the time period under study. The 
age of the patients ranged from 16 to 63 years (Mean 
:43.71+10.756 years) in Group A and 17 to 65 years 
(Mean :42.77+ 12.238 years) in Group B. Both the 
groups had  males (22.9%) and females(77.1%) 
respectively. Endoscopic staging (post treatment) 
showed stage 3 for right nostril in group A was 34.3% 
and in Group B it was 14.3%. Similarly in left nostril 
stage 3 nasal polyp in Group A was 32.9% and in 
Group B it was14.3%. Nasal polypi stage 2 observed in 
Group A on right side was 22.9% and 14.3% in Group 
B and on left side it was 21.4% in Group A and 14.3% 
in Group B. Chi Square test was applied to compare 
the efficacy of the treatment. Comparison of post 
treatment improvement in patency showed 61.4% & 
81.4% respectively (Table 2&3).Chi square test was 
applied to compare the efficacy which was statistically 
significant (p-value 0.009) which showed topical 
steroid were more effective than systemic steroids for 
right nostril. Similarly for left nostril Chi square test 
was statistically significant (p-value 0.005) giving the 
same results (Table 1-3). 
 
Table 2 : Comparison of Post Treatment Endoscopic 
Staging (right nostril) 
 Groups  
Flixonase 
Oral 
prednisolone 
Post-
treatment 
endoscopic 
staging 
(right 
nostril) 
No polyp 0(.0%) 16(22.9%) 
Restricted to 
middle 
meatus 
30(42.9%) 34(48.6%) 
Below 
middle 
turbinate 
16(22.9%) 10(14.3%) 
Massive 
polyposis 
24(34.3%) 10(14.3%) 
Total 70(100.0%) 70(100.0%) 
 
Table3:Comparison of post treatment 
endoscopic staging (left nostril) 
 Groups  
Flixonase 
Oral 
prednisolone 
Post-
treatment 
endoscopic 
staging        
                    
    (left 
nostril) 
No polyp 0(.0%) 16(22.9%) 
Restricted to 
middle 
meatus 
32(45.7%) 34(48.6%) 
Below 
middle 
turbinate 
15(21.4%) 10(14.3%) 
Massive 
polyposis 
23(32.9%) 10(14.3%) 
Total 70(100.0%) 70(100.0%) 
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Discussion 
Chronic rhinosinusitis is an inflammatory disease of 
the nasal and paranasal sinuses that is present for 
more than three months, and is associated with 
inflammatory changes ranging from polypoid mucosa 
to gross nasal polyp.11 The reported prevalence of NP 
varies between 0.2% and 4.3% of the population, and 
Larsen and Tos estimated an incidence of 0.627 per 
thousand per year in Denmark in symptomatic 
patients.12 The word polyp is derived from Greek, 
meaning many footed (poly, many; pous, footed) but a 
polyp has only one foot(stalk).13 Nasal polypi should 
probably be considered as one form of chronic 
inflammation in the nose and sinuses, i.e. part of 
chronic rhinosinusitis.14 They are frequently observed 
in chronic rhinosinusitis, including allergic 
rhinosinusitis, and other chronic sinonasal 
inflammatory states.15 
NPs are the common end-point of a number of 
conditions characterized by inflammation and are 
rarely 'curable' in its true sense. After consideration of 
the underlying etiology and confirmation of the 
diagnosis, they are normally managed by a 
combination of medical and surgical interventions. 
Surgical options include polypectomy and functional 
endoscopic sinus surgery (FESS). While in medical 
treatment topical corticosteroids have proved to be the 
treatment of choice. The efficacy of topical 
corticosteroids such as betamethasone sodium 
phosphate nasal drops, beclomethasone dipropionate, 
 fluticasone propionate and budesonide nasal sprays 
in reducing polyp size and rhinitis symptoms has been 
demonstrated in several randomized, placebo-
controlled trials. 
Topical corticosteroid spray is usually administered by 
nasal inhalation using a metered-dose nasal spray 
pump.16 If used once daily, it is administered 
preferably in the morning17. Generally, therapy is 
initiated with once-daily dosing; some patients may 
obtain greater relief with twice-daily divided dosing.16 
 However these nasal sprays have their own side 
effects. Mild, transient nasal burning and stinging ,  
after-taste, epistaxis , headache, nausea, vomiting, 
abdominal bloating, pharyngitis, cough and asthma  
are most common.16-19        
NPs  usually start in the osteomeatal region and block 
the normal sinus ventilation causing facial and sinus 
pain, infection and increasing nasal obstruction as they 
grow and protrude down and forward into the nasal 
passages. Because the pathway that leads to the 
formation of sinonasal polyps has not been completely 
elucidated, effective long-term treatments remain 
difficult to pinpoint. 
Management of these polyps, therefore, is a difficult 
challenge for the contemporary otolaryngologist. As 
per classical teaching ethmoidal polyps are more 
commonly seen in adults and elderly people and they 
are usually bilateral. They affect more men than 
women and typically appear in adults. Endoscopic 
sinus surgery is frequently used when medical therapy 
is insufficient. 
In our study the age of patient in Group A (flixonase) 
with ranges from 16 years to 63 years, whereas in 
group B (oral prednisolone) with ranges from 17 years 
to 65 years. Distribution of gender (male & female) 
were also calculated in both the groups in which 
frequency and percentages of male patients in both the 
groups were 16 (22.9%) and 16 (22.9%) respectively, 
whereas female patients in both the groups were 54 
(77.1%) and 54 (77.1%) respectively. 
Endoscopic staging (post-treatment) to see the polyps 
was also calculated in both the groups in right nostril. 
There were 04 stages of endoscopic stages which were 
seen in which frequency and percentages of restricted 
to middle meatus in both the groups were 30 (42.9%) 
and 34 (48.6%) respectively. Similarly massive 
polyposis in both the groups were 24 (34.3%) and 10 
(14.3%) respectively, where no patient was appear 
with ‘no polyp’ in group A and 16 (22.9%) with ‘no 
polyp in group B. 
Endoscopic staging (post-treatment) to see the polyps 
was also calculated in both the groups in the left 
nostril in which frequency and percentages of 
restricted to middle meatus in both the groups were 32 
(45.7%) and 34 (48.6%) respectively. Similarly massive 
polyposis in both the groups were 23 (32.9%) and 10 
(14.3%) respectively, where no patient was appear 
with ‘no polyp’ in group A and 16 (22.9%) with ‘no 
polyp in group B. Patency was restored in 42 (60%) 
patients in group A and 57 (81.4%) patients in group B. 
In our study, the female patients were more in number 
as compared to male patients because of the fact that 
female patients are entitled in our study place at Fauji 
Foundation Hospital Rawalpindi while male patients 
have entitlement in Military Hospital Rawalpindi 
except for non pensioners patients and Foundation 
employees. In topical group no patient had reduced to 
stage 0 while in oral steroid group 16 patients were 
reduced to stage 0. This is most probably because 
topical steroid cannot reach the middle meatus 
properly. Total 23 patients did not respond to topical 
steroid in stage 4 while total of 10 patients did not 
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respond to treatment in stage 4, so topical steroid is 
less effective in massive polyposis. 
Although topical steroids are usually applied via nasal 
spray, one paper has demonstrated efficacy of manual 
application directly into the frontal sinus; many other 
rhinologists have begun to advocate the off-label use 
of stronger steroids such as Pulmicort for use in nasal 
washes or applied directly as nasal drops20.In one 
study systemic steroids were shown to be more potent 
and more effective in decreasing polyp eosinophilia 
when compared with steroid sprays.21 
Conclusions 
1.Topical steroids are significantly effective than 
systemic steroids in treating nasal polyps. 
2.Intranasal steroids will not eliminate polyps, but the 
treatment clearly reduces their size. On the other hand, 
an effect on polyps in the middle meatus cannot be 
expected as only a small fraction of the spray reaches 
the middle meatus.   
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